Hydromorphone Quintian (Hydromorphone Hydrochloride)

• Hydromorphone is an opioid analgesic used to treat pain conditions that involve the central nervous system.
• Acute postoperative pain: provides rapid relief of severe pain following surgical procedures.
• Cancer‑related pain: helps control persistent moderate to severe pain associated with malignant disease.
• Severe trauma pain: reduces intense pain resulting from major injuries such as fractures or burns.
• Chronic non‑cancer pain: may be prescribed when other analgesics are ineffective.

• Hydromorphone exerts its analgesic effect by binding with high affinity to the µ‑opioid receptors in the central nervous system. Activation of these G‑protein‑coupled receptors inhibits adenylate cyclase, reduces calcium influx, and increases potassium efflux, leading to neuronal hyperpolarization and diminished transmission of nociceptive signals, thereby producing analgesia, sedation, and dose‑related respiratory depression.

Hydromorphone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea
• Constipation
• Drowsiness
• Dizziness
• Dry mouth
• Sweating

Serious or Rare Side Effects

• Respiratory depression
• Severe hypotension
• Anaphylactic reaction
• Adrenal insufficiency
• Seizures
• Opioid dependence or addiction

• When using Hydromorphone, careful clinical monitoring and individualized risk assessment are essential.
• Dose titration: adjust dose gradually based on patient response and tolerability.
• Respiratory monitoring: observe for signs of respiratory depression, especially in opioid‑naïve patients.
• Concurrent CNS depressants: avoid or use with caution when combined with benzodiazepines or alcohol.
• Renal or hepatic impairment: consider dose reduction and close monitoring.
• Pregnancy and lactation: use only if benefit outweighs risk; consult a specialist.
• Store at controlled room temperature: keep in original container, protect from light and moisture.

Hydromorphone interacts with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Concomitant full µ‑opioid agonists: risk of profound respiratory depression.
• Benzodiazepines or barbiturates: may cause synergistic central nervous system depression.
• MAO inhibitors: can precipitate severe hypertension or serotonin syndrome.
• Potent CYP3A4 inhibitors (e.g., ketoconazole): increase hydromorphone plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce analgesic efficacy.
• Anticholinergic agents: may worsen constipation.
• Diuretics: may enhance hypotensive effect.
• Serotonergic drugs: monitor for signs of serotonin syndrome.